Ximerakis, Methodios http://orcid.org/0000-0002-2815-7558
Holton, Kristina M.
Giadone, Richard M. http://orcid.org/0000-0003-4523-3062
Ozek, Ceren
Saxena, Monika
Santiago, Samara http://orcid.org/0000-0002-9502-7104
Adiconis, Xian
Dionne, Danielle
Nguyen, Lan
Shah, Kavya M. http://orcid.org/0000-0002-8722-4095
Goldstein, Jill M.
Gasperini, Caterina
Gampierakis, Ioannis A.
Lipnick, Scott L.
Simmons, Sean K.
Buchanan, Sean M.
Wagers, Amy J.
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Levin, Joshua Z. http://orcid.org/0000-0002-0170-3598
Rubin, Lee L. http://orcid.org/0000-0002-8658-841X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK007529)
Glenn Family Foundation
Howard Hughes Medical Institute
Broad Institute | Stanley Center for Psychiatric Research, Broad Institute
Klarman Cell Observatory, Broad Institute of MIT and Harvard
Simons Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1R01NS117407)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (5R01AG072086)
Article History
Received: 19 May 2022
Accepted: 30 January 2023
First Online: 9 March 2023
Competing interests
: L.L.R. is a founder of Elevian, Rejuveron and Vesalius Therapeutics, a member of their scientific advisory boards and a private equity shareholder. All are interested in formulating approaches intended to treat diseases of the nervous system and other tissues. He is also on the advisory board of Alkahest, a Grifols company, focused on the plasma proteome. None of these companies provided any financial support for the work in this paper. A.J.W. is a scientific advisor for Kate Therapeutics and Frequency Therapeutics, and is a founder of Elevian, Inc. and a member of their scientific advisory board and shareholder. Elevian, Inc. also provides sponsored research to the Wagers lab. A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until 31 August 2020 was a SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From 1 August 2020, A.R. has been an employee of Genentech, a member of the Roche Group. M.X. has been an employee of Merck & Co. since August 2020. The remaining authors declare no competing interests.